ITS
InsiderTrading
TradesInsidersCompaniesCluster BuysRankingsAbout
ITS
InsiderTrading Screener

Track SEC Form 4 insider trades. See what corporate insiders are buying and selling.

Browse

  • Trades
  • Insiders
  • Companies
  • Cluster Buys
  • Rankings

Top Insiders

  • Mark Zuckerberg
  • Elon Musk
  • Jamie Dimon
  • Satya Nadella
  • Lisa Su
  • Jensen Huang

Screeners

  • CEO & CFO Purchases
  • Director Purchases
  • Top Buys This Week
  • Top Sales This Week
  • 10b5-1 Trades
  • Buy/Sell Ratios
  • Politician Overlap
  • Sectors

Learn

  • Learn
  • What is a Form 4?
  • About & Methodology
  • What are Cluster Buys?
  • Top Insider Rankings
  • Privacy Policy
  • Terms of Use

Data

  • SEC EDGAR Form 4 ↗
  • CongressStock.com ↗
  • Track13F.com ↗
  • About the data
© 2026 InsiderTradingScreener.com. Data from SEC EDGAR Form 4 filings.For informational purposes only. Not financial advice.
Home / Trades / #496346

Warren Eric sold MLYS

July 21, 2026 · Form 4 insider transaction

Warren Eric sold 7,438 shares of Mineralys Therapeutics, Inc. at $26.87 per share, a transaction worth $199.9K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Disposed (sell-side)
Shares
7,438
Price
$26.87
Total value
$199.9K
InsiderWarren Eric
Role—
CompanyMineralys Therapeutics, Inc. (MLYS)
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateJuly 21, 2026
Filing dateJuly 23, 2026
Shares owned after38,400
OwnershipDirect
10b5-1 planYes
AmendedNo

Footnotes

These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.; The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.53 to $27.09. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

View the original Form 4 on SEC EDGAR